Shares of Balaxi Pharmaceuticals gained around 11 per cent on Monday, i.e. June 9, 2025, after the company shared updates related to its expansion along with financial results for the January-March quarter of FY25. The stock opened at Rs 52.90 on the National Stock Exchange against the previous close of Rs 51.95. The counter gained further and touched the high of Rs 57.50, a gain of 10.68 per cent. Last seen, it held firmly in green at Rs 54.96. The 52-week high of the stock is Rs 133, and the 52-week low is Rs 49.20.
The stock trades higher than the 5-day and 20-day moving averages but lower than the 50-day, 100-day and 200-day moving averages.
Global Expansion
The company has informed exchanges about its global growth strategy. The company said that it is planning to foray into Latin American countries, Southeast and CIS markets and wants to replicate the established and differentiated business model.
The company also said that it plans for backwards integration of the supply chain by setting up its first pharma formulation manufacturing facility.
It will also focus on the ideal mix of branded and generic medicines, maximising returns in key geographies. The company said that in the next five years, it will be targeting a strong global presence in potential frontier markets.
FY25 Earning
For the full financial year of 2025, the company has posted a net profit of Rs 25 crore, a recovery from a net loss of Rs 2.39 crore in FY24. However, the company's net profit in the March quarter of FY25 fell 21 per cent to Rs 8.64 crore from Rs 10.9 crore in the same quarter a year ago.
Stock Market Today
Meanwhile, equity benchmark indices Sensex and Nifty surged in early trade today amid a positive rally in global markets and positive sentiments among investors following the Reserve Bank of India's unexpected 50 basis point repo rate cut.
(This article is for informational purposes only and should not be construed as investment, financial, or other advice.)